Search
Olopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations
Mixtures: OFNOL FRESH % 0.1 + %0.15 STERİL OFTALMİK ÇÖZELTİ, 1 ADETProducts: PALLADA-NS %6.65 MG/ML NAZAL SPREY, 30 ML, OLAMİS 6,65 MG/ML NAZAL SPREY, ÇÖZELTİ, 30 MLAcylcarnitine 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine
smpdb.ca/view/SMP0123552Metabolic-1-en-1-yl]-3-oxocyclopentyl]heptanoylcarnitine. … inner membrane to once again form 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl-CoA and L-carnitine. 7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreAcylcarnitine (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine
smpdb.ca/view/SMP0123561MetabolicIn forming an acylcarnitine derivative, (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl-CoA reacts with L-carnitine to form (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1 … inner membrane to once again form (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoyl-CoA and L-carnitine. (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreBrolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigational[L9089] Brolucizumab was granted FDA approval in October 2019.[L9089]
Products: Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adet, Pagenax 120mg/ml Solution For InjectionD-alpha-Tocopherol acetate
go.drugbank.com/drugs/DB14002ApprovedNutraceuticalVet approvedThe recommended dietary allowances (RDAs) for vitamin E alpha-tocopherol are: males = 4 mg (6 IU) females = 4 mg (6 IU) in ages 0-6 months, males = 5 mg (7.5 IU) females = 5 mg (7.5 IU) in ages 7-12 months … = 15 mg (22.4 IU) females = 15 mg (22.4 IU) pregnancy = 15 mg (22.4 IU) lactation = 19 mg (28.4 IU) in ages 14+ years [L2120].
Synonyms: Vitamin E acetate, D-Mixtures: IQQU Advanced Sunscreen SPF 50, Coen.q10w.vit.c and E Beta-car.se Cu Zn MnErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalwith locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 … [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic
Products: BALVERSA 4 MG FİLM KAPLI TABLET, 28 ADET, BALVERSA 5 MG FİLM KAPLI TABLET, 28 ADETAxitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalIt is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative. … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamideMiglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat was first developed as an anti-HIV agent in the 1990s. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.
Synonyms: N-butyl-1-deoxynojirimycin, N-(n-Butyl)deoxynojirimycinCategories: Heterocyclic Compounds, 1-RingOrnithine
go.drugbank.com/drugs/DB00129ApprovedInvestigationalNutraceuticalProduced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine.
Mixtures: PEDASEL %10 AMİNO ASİT ÇÖZELTİSİ, 250 ML, AMINOPLASMAL-10% E INFUSIONProducts: HEPA-ORNITAT 5 G/10 ML INFÜZYON KONSANTRESI, 10 ADET, HEPALORNİTİN 5 G / 10 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 10 ADETRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigational[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer.
Synonyms: (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanoneProducts: EVISTA 60 MG TABLET, 28 ADET, ROXIMAX 60 MG FİLM TABLET, 28 ADET